InnoCare Pharma Limited INCPF
1.60 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
1.60 Day range 1.60
1.55 52-week range 3.26
- YTD
- -21.95%
- 1 year
- -50.92%
- Market cap
- 2.83B
- EPS (ttm)
- 0.08
- P/E ratio
- 20.00
- YTD return
- -21.95%
- 1-year return
- -50.92%
- Volume
- 200
- Avg volume
- 42
- Open
- 1.60
- Previous close
- 1.60
- Day's range
- 1.60 – 1.60
- 52-week range
- 1.55 – 3.26
- Earnings date
- Aug 25, 2026
6M +0.05 (+3.23%)
Next earnings
Aug 25, 2026
Expected Aug 25, 2026. Consensus EPS estimate -0.01265.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 25, 2026 | Jun 30, 2026 | -0.01265 | — | — | — |
| Apr 23, 2026 | Mar 31, 2026 | -0.02786 | 0.0087 | +0.04 | +131.23% |
| Mar 25, 2026 | Dec 31, 2025 | — | 0.05718 | — | — |
| Nov 13, 2025 | Sep 30, 2025 | — | -0.00281 | — | — |
| Aug 19, 2025 | Jun 30, 2025 | — | -0.00552 | — | — |
| May 13, 2025 | Mar 31, 2025 | — | 0.00138 | — | — |
News
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion 
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript 
China's Innocare's psoriasis drug meets main goal in late-stage trial 
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China 
Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR 
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released 
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China 
InnoCare Announces Approval of Orelabrutinib in Australia 
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released 
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Your note
Sign in to keep a note on INCPF — it syncs with the Stock Master app.